Novo Nordisk shares dive after heart medicine fails trial

Novo Nordisk shares declined after the experimental heart medicine ziltivekimab failed to demonstrate a statistically significant reduction in major cardiovascular adverse events. The company announced the trial results, which did not meet its primary endpoint.